Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients
NCT ID: NCT04587856
Last Updated: 2024-10-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
38 participants
INTERVENTIONAL
2021-02-12
2025-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT
NCT02872662
Cohort Study Assessing the Treatment Strategy for High-Risk Myelodysplastic Syndromes in Patients Under 70
NCT05367583
Immunophenotyping of Blood Cells in the Diagnosis Work-up of Myelodysplastic Syndromes
NCT03621241
Allogeneic HSCT in MDS Patients Based on Risk According to R-IPSS
NCT04801563
Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)
NCT02085798
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Viable bone marrow samples will be collected and cryopreserved from MDS patients before transplantation and at clinical disease recurrence.
CD34+ blast cells at disease relapse after HSCT will be compared with CD34+ cells collected before transplant by using Single-cell sequencing.
To study genomic and transcriptomic changes in CD34+ blast cells at disease relapse after HSCT will be used TARGET-seq in parallel with unbiased whole-transcriptome analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Biological evaluation
evaluation of molecular changes in CD34+ blast cells at the time of relapse after allo-HSCT.
bone marrow withdrawal
bone marrow samples evaluation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bone marrow withdrawal
bone marrow samples evaluation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18y or older
* Patients who will receive allogeneic stem cell transplantation (HSCT)
* Signed written informed consent according to ICH/EU/GCP and national local laws
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gruppo Italiano Malattie EMatologiche dell'Adulto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto
Bari, , Italy
Unità di Ricerca e di Malattie del sangue - Ematologia S. Luca Vecchio
Florence, , Italy
AOU San Martino-IST-Ematologia 1
Genova, , Italy
Sezione di Ematologia - Ospedale S.Maria della Misericordia
Perugia, , Italy
Dip. di Medicina Trasl. E di Precisione - U.O.C. Ematologia
Roma, , Italy
Policlinico Tor Vergata
Roma, , Italy
Ististuto Clinico Humanitas - Rozzano - Uo Oncologia Medica Ed Ematologia
Rozzano, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Valeria Santini
Role: primary
Carmela Di Grazia
Role: primary
Cristina Mecucci
Role: primary
Massimo Breccia
Role: primary
Maria Teresa Voso
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MDS0620
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.